335 related articles for article (PubMed ID: 6366135)
1. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.
Fisher B; Redmond C; Brown A; Wickerham DL; Wolmark N; Allegra J; Escher G; Lippman M; Savlov E; Wittliff J
J Clin Oncol; 1983 Apr; 1(4):227-41. PubMed ID: 6366135
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.
Fisher B; Redmond C; Brown A; Fisher ER; Wolmark N; Bowman D; Plotkin D; Wolter J; Bornstein R; Legault-Poisson S
J Clin Oncol; 1986 Apr; 4(4):459-71. PubMed ID: 2856857
[TBL] [Abstract][Full Text] [Related]
3. Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy.
Fisher B; Redmond CK; Wickerham DL; Rockette HE; Brown A; Allegra J; Bowman D; Plotkin D; Wolter J
Breast Cancer Res Treat; 1983; 3(4):355-64. PubMed ID: 6365208
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
5. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
7. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
8. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis.
Oriana S; Coradini D; Sasso GM; Di Fronzo G
Anticancer Res; 1991; 11(6):2199-205. PubMed ID: 1776861
[TBL] [Abstract][Full Text] [Related]
10. Tumor nuclear grade, estrogen receptor, and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer.
Fisher B; Fisher ER; Redmond C; Brown A
Breast Cancer Res Treat; 1986; 7(3):147-60. PubMed ID: 3535933
[TBL] [Abstract][Full Text] [Related]
11. Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: an interim report.
Fisher B
Breast Cancer Res Treat; 1983; 3 Suppl():S7-17. PubMed ID: 6367863
[TBL] [Abstract][Full Text] [Related]
12. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
13. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
Goldhirsch A; Gelber R
NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
[TBL] [Abstract][Full Text] [Related]
16. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience.
Fisher B; Redmond C; Fisher ER; Wolmark N
NCI Monogr; 1986; (1):35-43. PubMed ID: 3534589
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience.
Fisher B; Redmond C; Wickerham DL; Bowman D; Schipper H; Wolmark N; Sass R; Fisher ER; Jochimsen P; Legault-Poisson S
J Clin Oncol; 1989 May; 7(5):572-82. PubMed ID: 2651576
[TBL] [Abstract][Full Text] [Related]
18. Treatment of primary breast cancer with chemotherapy and tamoxifen.
Fisher B; Redmond C; Brown A; Wolmark N; Wittliff J; Fisher ER; Plotkin D; Bowman D; Sachs S; Wolter J; Frelick R; Desser R; LiCalzi N; Geggie P; Campbell T; Elias EG; Prager D; Koontz P; Volk H; Dimitrov N; Gardner B; Lerner H; Shibata H
N Engl J Med; 1981 Jul; 305(1):1-6. PubMed ID: 7015139
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
[TBL] [Abstract][Full Text] [Related]
20. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
